Abivax Shares Rise 5.11% at Close Despite a Declining CAC 40
Abivax shares closed on Tuesday, December 9th at 105 euros on Euronext Paris, marking a 5.11% increase from the previous day. This rise goes against the grain of a pressured Parisian market, with the CAC 40 dropping 0.69% to 8,052 points. The biotechnology company continues its upward trajectory that began several months ago, driven by positive results from its phase 3 clinical trials.
Market Performance and Share Dynamics
The share price opened slightly above the previous close of 99.90 euros, adding 5.10 euros during the session to settle at 105 euros. Trading volumes remained modest, accounting for 0.15% of the capital, indicating limited liquidity for the stock. Over the week, Abivax has seen a slight decline of 1.13%, but this drop is negligible compared to the quarterly performance. Over three months, the stock has soared by 39.44%, consolidating an exceptional dynamic that has seen the share value increase more than thirteenfold since the beginning of the year, with an annual increase of 1,216%. This performance significantly places the Parisian biotech at the forefront of the French market's gains, far ahead of the CAC 40's rise of 8.42% over the same period.
Key Developments in Clinical Trials
The stock took a decisive turn in July following the announcement of positive results for its two phase 3 trials, ABTECT-1 and ABTECT-2, evaluating its drug candidate obefazimod for the treatment of ulcerative colitis. This announcement triggered a historic surge in the share price, allowing the company to raise 747.5 million dollars through a public offering on the Nasdaq at the end of July. Patient-reported outcomes, revealed in November, confirmed a significant improvement in quality of life under treatment. The company is now awaiting 44-week maintenance data, expected in the second quarter of 2026, which is the final step before considering a request for authorization from the FDA and the European Medicines Agency in the second half of 2026.
Technical Analysis and Stock Behavior
Technically, the stock is trading in a broad channel between a support at 81.70 euros and a resistance at 111.80 euros, with high volatility of 18.43% over a month. The RSI is at 51, in a neutral zone, suggesting a balance between buyers and sellers. The share price is now significantly above its 50-day moving average at 88.60 euros, and even more so above its 200-day average at 41.34 euros, indicating a decidedly bullish underlying trend. Bollinger Bands frame the stock between 86.10 euros and 114.58 euros, with the price positioned in the upper part of this range. With a beta of 0.09, Abivax shows a low correlation with the overall market, explaining its ability to progress independently of the CAC 40's downward trend during the session.
